Items Tagged ‘liposarcoma’

February 4th, 2016

Halaven Approved for Liposarcoma

By

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven is already approved for the treatment of advanced breast cancer. The approval indication for Halaven in the treatment of […]

View full entry

Tags: eribulin, fda, Halaven, liposarcoma, News, Sarcoma, soft tissue sarcoma, Soft Tissue Sarcomas, STS


November 2nd, 2015

Yondelis® Approved for Treatment of Soft Tissue Sarcoma

By

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The approval of Yondelis is for patients whose cancer is not able to be removed by surgery and/or has spread to distant sites in the body. This treatment is approved […]

View full entry

Tags: advanced, leimyosarcoma, liposarcoma, News, Sarcoma, Soft Tissue Sarcomas, trabectedin, yondelis


October 20th, 2015

Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma

By

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or progressed following prior therapies. These results were recently published as a “rapid communication” in the Journal of Clinical Oncology. Liposarcoma and leiomyosarcoma are both types of soft-tissue sarcomas.  Soft tissue […]

View full entry

Tags: dacarbazine, DTIC, leiomyosarcoma, liposarcoma, News, Sarcoma, Soft Tissue Sarcomas, trabectedine, yondelis